XRTX — XORTX Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1729214 ·
Last close
$1.06
Market Cap
$1.93M
52W High
$3.60
52W Low
$0.81
ADV30
1,183,695
Next earnings
2026-11-12

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -1,690,650 -1,690,734 6,184,197 994,045 679,522
Mar 2026 0 — -823,297 -808,472 2,144,791 250,275 860,988
Dec 2025 0 — -686,416 -590,462 2,683,530 864,514 599,071
Sep 2025 0 — -716,197 -649,469 2,811,078 1,193,915 837,408

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,100,467
Investing CF
$-417,123
Financing CF
$5,456,493
CapEx
$-177,393
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.23
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-26,323,763
Inventory
—
Receivables
$88,090
ST Investments
—
EBIT TTM
$-3,916,560
Pretax Income TTM
$-3,739,137
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -3,256,014 -2,656,304 2,683,530 599,071 2,084,459 -2,768,723
Dec 2024 0 -4,118,319 -3,313,346 4,094,527 757,990 3,336,537 -3,678,648
Dec 2023 0 -6,045,986 -2,158,065 5,467,964 825,938 4,642,026 -6,583,165
Dec 2022 0 -10,290,606 -7,718,882 12,374,026 5,377,215 6,996,811 -8,165,959

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.80

Peers — same industry

TickerNameMarket CapLastDaily %
PPCB Propanc Biopharma, Inc. $1.94M $1.88 —
ACUT Accustem Sciences Inc. $1.90M $0.12 —
JAGX Jaguar Health, Inc. $1.96M $0.38 —
SXTP 60 DEGREES PHARMACEUTICALS, INC. $1.88M $0.53 —
JUNS JUPITER NEUROSCIENCES, INC. $2.00M $1.52 —

News headlines (Yahoo Finance, 1h cache)

XORTX Completes Manufacturing of Clinical Drug Supply
2026-11-16 13:05 · Yahoo
XORTX Patent Allowed for XRx-101 Program by Japan Patent Office
2026-11-13 17:00 · Yahoo
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
2026-09-10 20:05 · Yahoo
XORTX Re-Engages Investor Relations Program
2026-09-08 22:15 · Yahoo
XORTX Announces Termination and Postponement of Investor Relations Program
2026-08-28 11:00 · Yahoo
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
2026-10-08 20:00 · Yahoo
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
2026-09-18 12:05 · Yahoo
XORTX Announces Director Resignation
2026-07-31 21:00 · Yahoo
XORTX Appoints New Director
2026-07-29 11:00 · Yahoo
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
2026-06-15 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.